Saturday 17 October 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.47
0.93
−5.34%
Follow IMNM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
21.57 | (0.01) | 1.00 | — | — | — | — | — | — |
P/S ratio |
149.04 | 68.88 | 15.59 | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
13.87 | (7.77) | (0.03) | — | — | — | — | — | — |
P/Operating CF |
(39.13) | (14.81) | (12.51) | — | — | — | — | — | — |
P/B ratio |
2.96 | 3.44 | 1.82 | — | — | — | — | — | — |
Price to Tangible BV |
2.96 | 3.44 | 1.82 | — | — | — | — | — | — |
EV/Sales |
97.17 | 44.90 | 5.77 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
(6.41) | (3.66) | (10.68) | — | — | — | — | — | — |
EV/FCF |
(6.10) | (3.44) | (9.62) | — | — | — | — | — | — |
Quick Ratio |
14.53 | 4.00 | 6.33 | 2.77 | 5.06 | 13.09 | 1.53 | 1.03 | — |
Current Ratio |
14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | 1.35 | — |
Net Debt/EBITDA |
2.92 | 0.71 | 1.26 | 0.56 | 2.01 | 3.41 | 0.20 | 0.06 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.12% | 11.15% | 26.44% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.17 | 0.51 | — |
Asset Turnover |
0.02 | 0.05 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.90 | 0.38 | 0.07 | 0.76 | 0.74 | 0.68 | 0.92 | 0.94 | — |
Capex/Depreciation |
(83.49) | 9.00 | (3.85) | (0.39) | (0.10) | (0.78) | (0.38) | (0.44) | — |
Interest Coverage |
— | — | — | 7,380.20 | (2,520.40) | (322.66) | (107.79) | (75.91) | — |
| (52.09%) | (194.63%) | (156.45%) | (115.73%) | (55.20%) | (624.22%) | 34.34% | 25.79% | — | |
| (46.00%) | (150.71%) | (123.77%) | (91.54%) | (48.24%) | (71.95%) | (219.69%) | (352.74%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (368.60%) | (503.31%) | (257.14%) | — |
Return on Tangible Assets |
(33.69%) | (165.38%) | (85.48%) | (234.50%) | (51.73%) | (43.10%) | (330.82%) | (298.06%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
2,554.19% | 1,432.83% | 164.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
630.57% | 364.51% | 140.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
370.12% | 174.18% | 44.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.33 | 0.26 | 0.53 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(11.27%) | (48.68%) | (48.96%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(10.69%) | (18.94%) | (3.84%) | — | — | — | — | — | — |
Revenue per Share |
0.08 | 0.15 | 0.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(2.19) | (1.89) | (0.38) | (2.37) | (1.58) | (3.58) | (8.78) | (6.81) | — |
Capex per Share |
(0.11) | (0.12) | (0.04) | (0.02) | (0.01) | (0.17) | (0.21) | (0.21) | — |
Free Cash Flow per Share |
(2.30) | (2.01) | (0.42) | (2.39) | (1.59) | (3.75) | (8.99) | (7.02) | — |
Cash per Share |
7.48 | 3.71 | 6.96 | 1.68 | 4.27 | 11.73 | 2.32 | 1.47 | — |
Shareholders Equity per Share |
7.26 | 3.09 | 6.04 | 1.37 | 4.18 | 12.20 | 2.98 | 2.12 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
7.26 | 3.09 | 6.04 | 1.37 | 4.18 | 12.20 | 2.98 | 2.12 | — |
Free Cash Flow |
(200.60) | (117.97) | (8.40) | (28.94) | (18.30) | (12.72) | (9.83) | (7.63) | — |
Working Capital |
615.79 | 167.03 | 122.87 | 15.32 | 46.91 | 39.86 | 1.46 | 0.55 | — |
Capital Expenditures |
(9.68) | (7.17) | (0.83) | (0.25) | (0.08) | (0.59) | (0.23) | (0.23) | — |
Net Current Asset Value |
611.93 | 162.26 | 116.05 | 15.26 | 46.90 | 39.71 | 1.33 | (0.03) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
1.40 | 0.79 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.01 | (0.08) | 0.10 | 0.93 | 0.88 | 0.49 | 0.36 | 0.25 | — |
Cash ROIC |
(15.58%) | (29.61%) | (3.26%) | (78.26%) | (18.79%) | (15.59%) | (154.34%) | (150.10%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 2.58 | 2.61 | 2.61 | — | — | — |
Average Payables |
8.76 | 8.75 | 2.86 | 2.74 | 2.13 | 0.87 | 0.51 | 0.51 | — |
Average Assets |
461.71 | 194.39 | 86.29 | 40.99 | 51.23 | 24.79 | 4.75 | 2.22 | — |
Average Common Equity |
407.75 | 150.52 | 68.27 | 32.42 | 44.77 | 2.86 | (30.42) | (30.42) | — |
Columns are period end dates